Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.39 USD | +2.92% | +0.68% | -37.87% |
04-29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
04-26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
Evolution of the average Target Price on Teladoc Health, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Teladoc Health, Inc.
UBS | |
Oppenheimer | |
Deutsche Bank Securities | |
Leerink Partners | |
Citigroup | |
Barclays | |
Piper Sandler | |
Canaccord Genuity | |
RBC Capital Markets | |
JPMorgan Chase | |
Evercore ISI | |
Stephens Inc. | |
Credit Suisse | |
Wells Fargo Securities | |
SVB Securities LLC | |
Berenberg Bank | |
DA Davidson | |
Guggenheim | |
Truist Securities | |
KeyBanc Capital Markets | |
Cowen | |
Needham & Co. | |
Goldman Sachs | |
Stifel Nicolaus | |
Argus | |
SVB Leerink | |
Baird | |
William Blair & Co. | |
Craig-Hallum | |
Jefferies & Co. | |
BTIG |
EPS Revisions
- Stock Market
- Equities
- TDOC Stock
- Consensus Teladoc Health, Inc.